Anthrax

• EMA withdrawal · 2024-09-09
  EMA Withdrawn: Nyxthracis (previously Obiltoxaximab SFL) (nyxthracis) — SFL Pharmaceuticals Deutschland GmbH

  EMA has withdrawn Nyxthracis (formerly Obiltoxaximab SFL) from the market for anthrax.

• EMA withdrawal · 2017-06-02
  EMA Application withdrawn: Solithromycin Triskel EU Services (solithromycin) — Triskel EU Services Ltd

  The EMA reports withdrawal of the Solithromycin application by Triskel EU Services Ltd for uses including tularemia, pneumonia, and anthrax.